. 2019 Apr 4;10(5):283–295. doi: 10.3892/br.2019.1204

Table VIII.

Glibenclamide response variability among Mexican patients with DMT2 according to CYP2C9 polymorphisms (*2, *3 and IVS8-109A>T).

	Fasting glucose (mg/dl) and glycemic control (<110 mg/dl)
	CYP2C9 genotypes
	1/1 (n)			1/2 (n)		1/3 (n)		2/3 (n)
Oral hypoglycemiant (n)	A/A	*A/T	*T/T	A/A	*A/T	A/A	*A/T	A/A
Glibenclamide (n=11)	127.65(6)^a	107.67(3)^a	121.00(1)^a			249.00(1)^a
	[103.42-151.88]	[71.86-143.48]
	33.33% (2)	66.67% (2)^b				0.00% (0)^a
Glibenclamide/metformin (n=112)	160.34(74)^a	149.97(20)^a	130.41(3)^a	139.56(7)^a	174.58(2)^a	169.12(4)^a	124.00(1)^a	148.00(1)^a
	[94.61-226.07]	[88.06-211.88]	[103.61-157.20]	[107.74-171.37]	[103.97-245.20]	[87.50-250.80]
	18.00% (13)	25.00% (5)	0.00% (0)^b	14.29% (1)	0.00% (0)^b	50.00% (2)^b	0.00% (0)	0.00% (0)
	HbA1c (%) and glycemic control (HbA1c< 6.5%)
	CYP2C9 genotypes
	1/1 (n)			1/2 (n)		1/3 (n)		2/3 (n)
Oral hypoglycemiant (n)	A/A	*A/T	*T/T	A/A	*A/T	A/A	*A/T	A/A
Glibenclamide (n=11)	5.68(6)^a	6.67(3)^a	6.40(1)^a			6.20(1)^a
	[2.81-8.55]	[5.82-7.52]
	33.33% (2)	33.33% (1)	100.00% (1)			100.00% (1)
Glibenclamide/metformin (n=112)	8.03(74)^a	8.11(20)^a	9.07(3)^a	8.17(7)^a	8.46(2)^a	8.82(4)^a	6.10(1)^a	6.40(1)^a
	[5.71-10.34]	[5.68-10.55]	[5.86-12.29]	[6.93-9.40]	[7.71-9.22]	[5.81-11.83]
	24.64% (18)	25.00% (5)	12.50% (1)^b	0.00% (0)^b	0.00% (0)^b	25.00% (1)	100.00% (1)	100.00% (1)

Values are expressed as ^a = median; IQR [-] = interquartile range; n, number of individuals;

^bP<0.05 (genotypes). CYP2C9, cytochrome P450 2C9.